Literature DB >> 191575

Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients.

M S Mahaley, W H Brooks, T L Roszman, D D Bigner, L Dudka, S Richardson.   

Abstract

Cellular and humoral immune parameters were evaluated in a series of brain-tumor patients, 42 with glioblastoma multiforme, 17 with other anaplastic gliomas, and 17 with meningiomas. A degree of anergy was found, which seems in the group as a whole to be proportional to the degree of anaplasia. In addition, serial bimonthyl testing in individual cases revealed further reduction in certain immune responses coincident with clinical decline.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 191575     DOI： 10.3171/jns.1977.46.4.0467

Source DB:  PubMed          Journal:  J Neurosurg        ISSN： 0022-3085            Impact factor:   5.115


  50 in total

1.  Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma.

Authors:  F P Holladay; T Heitz-Turner; W L Bayer; G W Wood
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

2.  TGF-beta2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors.

Authors:  Yang Liu; Qing Wang; B K Kleinschmidt-DeMasters; Alex Franzusoff; Ka-yun Ng; Kevin O Lillehei
Journal:  J Neurooncol       Date:  2006-08-29       Impact factor: 4.130

3.  Lymphocyte subsets in patients with brain tumors.

Authors:  M Uegaki; S Kobayashi; S Kuramoto; M M Yokoyama
Journal:  J Neurooncol       Date:  1988       Impact factor: 4.130

Review 4.  Adenoviral vector-mediated gene therapy for gliomas: coming of age.

Authors:  Maria G Castro; Marianela Candolfi; Thomas J Wilson; Alexandra Calinescu; Christopher Paran; Neha Kamran; Carl Koschmann; Mariela A Moreno-Ayala; Hikmat Assi; Pedro R Lowenstein
Journal:  Expert Opin Biol Ther       Date:  2014-04-29       Impact factor: 4.388

5.  The alteration of prostaglandin E2 levels in patients with brain tumors before and after tumor removal.

Authors:  Joon-Khim Loh; Shiuh-Lin Hwang; Ann-Shung Lieu; Tzuu-Yuan Huang; Shen-Long Howng
Journal:  J Neurooncol       Date:  2002-04       Impact factor: 4.130

6.  An experimental study of dendritic cells-mediated immunotherapy against intracranial gliomas in rats.

Authors:  Xinmei Zhu; Chuanzhen Lu; Baoguo Xiao; Jian Qiao; Yi Sun
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

7.  Immunologic status in children with brain tumors and the effect of therapy.

Authors:  R Kebudi; I Ayan; E Darendeliler; L Ağaoğlu; S Ekmekçioğlu; T Yağci; S Pişkin; N Bilge
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

8.  Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-alpha. Results of a phase I clinical trial.

Authors:  R E Merchant; D W McVicar; L H Merchant; H F Young
Journal:  J Neurooncol       Date:  1992-01       Impact factor: 4.130

9.  Particular features of cell-mediated immunity in patients with anaplastic gliomas. A comparison with kidney and bladder cancer patients.

Authors:  F Servadei; R Parente; M Bucci; E Beltrandi; F Tognetti; G Gaist
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

10.  Inability of mitogen-activated lymphocytes obtained from patients with malignant primary intracranial tumors to express high affinity interleukin 2 receptors.

Authors:  L H Elliott; W H Brooks; T L Roszman
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.